even more dramatically, that it reduces mortality when delivered in the adjuvant setting. Subsequently developed anti-HER2 agents have even further improved survival in patients with HER2-positive breast cancer, including another monoclonal antibody
Since then, several clinical trials have shown that trastuzumab improves overall survival in patients with HER2-positive metastatic breast cancer and, even more dramatically, that it reduces mortality when delivered in the adjuvant setting. Subsequently developed anti-HER2 agents have even further improved...
Since then, several clinical trials have shown that trastuzumab improves overall survival in patients with HER2-positive metastatic breast cancer and, even more dramatically, that it reduces mortality when delivered in the adjuvant setting. Subsequently developed anti-HER2 agents have even further improved...
这种分类对于确定乳腺癌的预后是否也有一定价值,目前仍存在争议。近期,青岛大学附属医院乳腺病诊疗中心王海波教授带领团队开展了一项回顾性研究,旨在基于条件生存(Conditional Survival,CS)分析开发HER2阴性乳腺癌复发转移风险的动态预测模型[1]。2024年1月19日,该研究全文发表于Ther Adv Med Oncol期刊。医学界肿瘤频道特此...
[5]Yoon KH, Park Y, Kang E, et al. Effect of estrogen receptor expression level and hormonal therapy on prognosis of early breast cancer[J]. Cancer Res Treat, 2021 [Ahead of print]. [6]Chen T, Zhang N, Moran MS, et al. Borderline ER-positive primary breast cancer gains no signific...
prognosisSEERBackground Bone is the most common metastatic site of breast cancer. The developmental pattern of bone metastasis differs in different molecular subtypes. The prognostic factors of HER2‐positive breast cancer with bone metastases require further investigation. The goal of this retrospective ...
[12]Li Y, Maimaitiaili A, Qu F, Li G, Shi B, Wang Y, Zhang J, He J, Fan Z, Zhang H. Effect of HER2-low-positive status on neoadjuvant chemotherapy and survival outcome of breast cancer: a 10-year dual-center retrospective study. Am J Cancer Res. 2023 Aug 15;13(8):3571-358...
[5]Agostinetto E,et al.HER2-Low Breast Cancer:Molecular Characteristics and Prognosis.Cancers 2021;13:2824. [6]Allison KH,Dintzis SM,Schmidt RA.Frequency of HER2 heterogeneity byfluorescence in situ hybridization according to CAP expert panel recommendations:time for a new look at how to rep...
1. Zimin L, Mingpeng S, Xiaoxiao Li, et al. HER2 copy number as predictor of disease‑free survival in HER2‑positive resectable gastric adenocarcinoma. J Cancer Res Clin Oncol. 2021. doi: 10.1007/s00432-021-035...
[9]Lee HJ,et al.HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer.Am J Clin Pathol 2014;142:755–66. [10]Hanna WM,et al.HER2 in situ hybridization in breast cancer:clinical implications of polysomy 17 and genetic heterogeneity....